CBD shows promise in opioid relapse prevention trial

NCT ID NCT06940674

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 20 times

Summary

This study tests whether cannabidiol (CBD) can reduce cravings and prevent relapse in people with opioid use disorder who are already on medication like methadone or buprenorphine. About 450 adults will take CBD or a placebo for 24 weeks while continuing their usual treatment. The goal is to see if adding CBD helps them avoid using illicit opioids.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER (OUD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CODA Treatment Recovery
RECRUITING

Portland, Oregon, 97214, United States

Contact Email: •••••@•••••

Contact
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

OPIOID USE DISORDER (OUD)